Immatics N.V.(US:IMTX) GlobeNewswire News Room·2024-09-06 11:00Core Insights - Immatics N.V. announced updated clinical data on its lead cell therapy candidate, ACTengine® IMA203, targeting PRAME, to be presented at the 21st International Congress of the Society for Melanoma Research [1] Group 1: Clinical Data Presentation - The oral presentation is scheduled for October 11, 2024, from 8:00 to 8:20 am Central Daylight Time, during the Plenary Session 1 focused on Developmental Immunotherapy [2] - The presentation will be delivered by Dr. Martin Wermke from University Hospital Dresden, Germany, and will provide a clinical update on ACTengine IMA203 TCR-T targeting PRAME in PD1-refractory metastatic melanoma [2] Group 2: About ACTengine IMA203 - ACTengine® IMA203 is an autologous T cell product with a genetically modified TCR directed against a peptide derived from PRAME, which is frequently expressed in various solid cancers [2] - The PRAME peptide is characterized by high copy numbers per tumor cell and is specifically expressed in tumor tissue, indicating its potential for a broad cancer patient population [2] - Immatics utilizes its proprietary mass spectrometry-based target discovery platform, XPRESIDENT®, and TCR discovery and engineering platform, XCEPTOR®, to develop this targeted therapy [2] Group 3: Current Trials - ACTengine® IMA203 is currently being evaluated in a Phase 1 trial as a monotherapy and as a second-generation IMA203CD8 (GEN2) monotherapy, which combines both CD4+ and CD8+ T cells [3] - The combination of IMA203 with an immune checkpoint inhibitor has been deprioritized in the development pipeline [3] Group 4: Company Overview - Immatics focuses on discovering true targets for cancer immunotherapies and developing specific T cell receptors to enable robust T cell responses against these targets [4] - The company aims to deliver the power of T cells and unlock new treatment avenues for cancer patients through its pipeline of Adoptive Cell Therapies and TCR Bispecifics [4]